Group’s pre-tax loss narrows

EIRX Therapeutics has posted a narrower first half pre-tax owing to lower operating costs achieved over its last trading period.

In its statement the group also said its strategy going forward could include partnering with larger businesses.

Mergers and acquisitions opportunities to boost product development would also be considered as the group moves to broaden its operating base, it said.